Organon & Co.

NYSE:OGN

Drug Manufacturers - General

Healthcare
$13.92 +0.04%

+$0.01 today

Market cap
$3.66B
Beta
1.54
P/E (TTM)
14.2
EPS (TTM)
$0.94
Dividend yield
0.60%
52W Low $5.69High $13.49

Volume 3.90M

Average 8.57M

OGN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Organon & Co.NYSE: OGN

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $421M rose 1.4% year over year, ahead of the -2.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.0% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Selling, general & admin amounted to 27.5% of revenue in FY2025, unchanged from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $1.71B (-0.1%) for the fiscal year ending Dec 2026, a step up from the -2.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$421M-3.0% QoQ
Last fiscal yearDec 2025
$1.71B-2.8% YoY
LTMSep 2026
$1.71B-2.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%-1.5%-2.9 pp
1 year-2.8%-0.1%+2.7 pp
3-year CAGR+0.1%+2.8%+2.7 pp
5-year CAGR+1.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.71B USD
Year-over-year change
-2.8%
4-year CAGR
+0.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How OGN compares with its peers on the latest reported figures

  • OGN's LTM Sep 2026 selling, general & admin of $1.71B is the highest of the 10 companies compared; the peer median is $187.24M.
  • Its year-over-year change of -2.6% is the 5th highest of 10, against a peer median of -3.2%.
  • Selling, general & admin amounts to 28.1% of revenue for OGN, versus a peer median of 20.2%.
OGN Competitors Peer median
Selling, General & Admin for OGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGNOrganon & Co.LTM Sep 2026$1.71B -2.6%+0.1%28.1%
TLRYTilray Brands, Inc.LTM Feb 2026$367.31M -3.2%+15.1%31.1%
PAHCPhibro Animal Health CorporationLTM Mar 2026$302.55M +7.3%+11.9%20.2%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$272.47M +14.2%+18.5%28.4%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$224.83M -30.3%+13.0%15.4%
MDPediatrix Medical Group, Inc.LTM Sep 2026$187.24M -21.5%+1.3%9.6%
SEMSelect Medical Holdings CorporationLTM Mar 2026$160.79M -23.6%+0.3%2.9%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M +32.6%+68.1%93.3%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$100.97M -24.6%-19.7%32.4%
ALVOAlvotechLTM Mar 2026$98.01M +51.8%-21.3%17.5%
Peer median (excluding OGN) $187.24M-3.2%+11.9%20.2%

Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.3B6.17B6.26B6.4B6.22B
Cost of Revenue2.38B2.29B2.52B2.69B2.85B
Gross Profit3.92B3.88B3.75B3.72B3.36B
Gross Margin62.2%62.8%59.8%58.0%54.1%
Research & Development443M471M528M469M366M
Selling, General & Admin1.67B1.7B1.89B1.76B1.71B
Operating Expenses2.01B2.18B2.42B2.23B2.09B
Depreciation & Amortization195M212M236M277M361M
EBITDA1.98B1.76B1.44B1.6B1.29B
EBITDA Margin31.4%28.4%22.9%25.1%20.8%
Operating Income1.92B1.71B1.33B1.49B1.29B
Operating Margin30.4%27.6%21.2%23.2%20.7%
Interest Income00000
Interest Expense258M422M527M520M504M
Other Income / Expenses(386M)(583M)(654M)(679M)(860M)
Income Before Tax1.53B1.12B673M807M425M
Pre-Tax Margin24.3%18.2%10.7%12.6%6.8%
Income Tax Expense178M205M(350M)(57M)238M
Net Income1.35B917M1.02B864M187M
Net Margin21.4%14.9%16.3%13.5%3.0%
EPS (Basic)5.333.614.013.360.72
EPS (Diluted)5.333.593.993.330.72
Weighted Avg Shares253.55M254.08M255.24M257.05M259.5M
Weighted Avg Shares (Diluted)253.55M255.17M256.27M259.15M260.76M

Organon & Co.

NYSE:OGN

Intrinsic Alpha fair value

Locked

Current Price

$13.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.